The molecular etiology of human progenitor reprogramming into self-renewing leukemia stem cells (LSC) has remained elusive. Although DNA sequencing has uncovered spliceosome gene mutations that promote alternative splicing and portend leukemic transformation, isoform diversity also may be generated by RNA editing mediated by adenosine deaminase acting on RNA (ADAR) enzymes that regulate stem cell maintenance. In this study, wholetranscriptome sequencing of normal, chronic phase, and serially transplantable blast crisis chronic myeloid leukemia (CML) progenitors revealed increased IFN-γ pathway gene expression in concert with BCR-ABL amplification, enhanced expression of the IFN-responsive ADAR1 p150 isoform, and a propensity for increased adenosine-to-inosine RNA editing during CML progression. Lentiviral overexpression experiments demonstrate that ADAR1 p150 promotes expression of the myeloid transcription factor PU.1 and induces malignant reprogramming of myeloid progenitors. Moreover, enforced ADAR1 p150 expression was associated with production of a misspliced form of GSK3β implicated in LSC self-renewal. Finally, functional serial transplantation and shRNA studies demonstrate that ADAR1 knockdown impaired in vivo self-renewal capacity of blast crisis CML progenitors. Together these data provide a compelling rationale for developing ADAR1-based LSC detection and eradication strategies.
The molecular etiology of human progenitor reprogramming into self-renewing leukemia stem cells (LSC) has remained elusive. Although DNA sequencing has uncovered spliceosome gene mutations that promote alternative splicing and portend leukemic transformation, isoform diversity also may be generated by RNA editing mediated by adenosine deaminase acting on RNA (ADAR) enzymes that regulate stem cell maintenance. In this study, wholetranscriptome sequencing of normal, chronic phase, and serially transplantable blast crisis chronic myeloid leukemia (CML) progenitors revealed increased IFN-γ pathway gene expression in concert with BCR-ABL amplification, enhanced expression of the IFN-responsive ADAR1 p150 isoform, and a propensity for increased adenosine-to-inosine RNA editing during CML progression. Lentiviral overexpression experiments demonstrate that ADAR1 p150 promotes expression of the myeloid transcription factor PU.1 and induces malignant reprogramming of myeloid progenitors. Moreover, enforced ADAR1 p150 expression was associated with production of a misspliced form of GSK3β implicated in LSC self-renewal. Finally, functional serial transplantation and shRNA studies demonstrate that ADAR1 knockdown impaired in vivo self-renewal capacity of blast crisis CML progenitors. Together these data provide a compelling rationale for developing ADAR1-based LSC detection and eradication strategies.
A lthough advanced malignancies are diverse in phenotype, they often exhibit stem-cell properties including enhanced survival, differentiation, quiescence, and self-renewal potential (1, 2) . Early insights into the molecular pathogenesis of cancer stemmed from the discovery of the Philadelphia chromosome (Ph + ) and its constitutively active BCR-ABL1 tyrosine kinase in chronic myeloid leukemia (CML) (3) (4) (5) . Tyrosine kinase inhibitor (TKI) therapy targeting BCR-ABL1 suppresses CML during the chronic phase (CP) of the disease in most patients able to tolerate long-term therapy (6) . Although the CP stage of CML often can be controlled for long periods of time with standard TKI therapies, subsequent genetic and epigenetic alterations promote progenitor expansion and the generation of self-renewing leukemia stem cells (LSC) that fuel disease progression and blast crisis (BC) transformation along with TKI resistance (7, 8) . Furthermore, TKI discontinuation usually results in CML resurgence, suggesting that quiescent progenitors persist despite therapy (9) (10) (11) (12) .
Mutations in spliceosome genes and alternative splicing of coding and noncoding RNAs are emerging as important drivers of transcriptomic diversity that fuel leukemic progression and therapeutic resistance (7, 8, 13) . Moreover, previous studies reveal extensive RNA editing in the human transcriptome (14) (15) (16) (17) , primarily in primate-specific Alu sequences (18) (19) (20) , which promotes splice isoform diversity. RNA editing activity is mediated by the adenosine deaminase acting on dsRNA (ADAR) family of editases (21) , which includes ADAR1 (also known as ADAR), ADAR2 (ADARB1), and ADAR3 (ADARB2). ADAR1 and ADAR2 are active in embryonic cell types (18) , and ADAR3 may play a nonenzymatic regulatory role in RNA editing activity (22) . ADAR enzymes regulate fetal and adult hematopoietic stem cell (HSC) maintenance and stem cell responses to inflammation (23) (24) (25) (26) . ADAR-mediated adenosine-to-inosine (A-to-I) RNA editing in an Alu sequence containing dsRNA hairpin structures (14, 20) can generate alternative donor or acceptor splice sites (27, 28) , alter RNA structure (21) , modulate regulatory RNAs and gene silencing activities (29) , and introduce codon sequence alterations (29) . Interestingly, ADAR deregulation has been implicated in a variety of malignant cell types (30, 31) . However, the functional effects of RNA editing in leukemia have not been elucidated. Here we examined the role of ADAR1-mediated RNA editing in malignant reprogramming of myeloid progenitors into LSC that drive BC transformation in CML.
Whole-transcriptome sequencing coupled with quantitative RT-PCR (qRT-PCR) analysis demonstrated increased IFN-responsive ADAR1 expression in LSC from primary BC CML patient samples as compared with CP CML and normal cord blood progenitors. This increase coincided with enhanced expression of inflammatory pathway genes during the progression from CP to BC. Moreover, ADAR1 p150 mRNA expression correlated with BCR-ABL amplification and increased A-to-I editing with differential expression of ADAR target genes in BC CML. Lentiviral ADAR1 p150 expression induced PU.1 expression that promotes expansion of myeloid progenitors and was associated with production of a misspliced form of glycogen synthase kinase (GSK)-3β that has been implicated in LSC self-renewal (7) . Lentiviral ADAR1 knockdown also reduced BC LSC self-renewal capacity in RAG2 −/− γc −/− mice. These data shed light on the contribution of ADAR1-mediated RNA editing to malignant progenitor reprogramming driving leukemic progression.
Results
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progenitor cells from primary CML patient samples (Table S1 ) using splice isoform-specific primers (Table S2 ). Expression levels of the inflammation-responsive ADAR1 p150 isoform were increased approximately eightfold in CML BC progenitors in comparison with normal cord blood (Fig. S1C ), but levels of the constitutively active p110 isoform did not differ significantly among groups (Fig. S1D) . Analysis of the ratio of p150 to p110 showed a relative enrichment of the p150 ADAR1 isoform associated with CML progression (Fig. 1B) and BCR-ABL amplification in BC CML progenitors (Fig. 1C) . We observed similar patterns of increased ADAR1 p150 expression in the granulocyte/macrophage progenitor (GMP) fraction of primary CML samples (Fig. S1E) , which expands during CML progression (Fig. S1F) (34) . To confirm sensitivity of HSC to inflammatory mediator-induced ADAR1 p150 expression, qRT-PCR analysis was performed on CD34
+ cord blood cells treated with IFN-γ or TNF-α, and results showed a twofold up-regulation of ADAR1 p150 (Fig. S1G) .
Additional analysis of ADAR family gene expression in the RNA-seq data demonstrated that although total ADAR1 (ADAR) expression was detectable in all samples, ADAR2 and ADAR3 expression was below detection thresholds (Fig. S2B ). This result is consistent with previous reports showing that ADAR1 is the most highly expressed RNA-editing enzyme in tumor cells (35, 36) and suggests that ADAR1 is likely the primary functional A-to-I RNA editase in CML LSC.
To investigate the contribution of ADAR1 up-regulation to RNA editing during CML progression, RNA-seq analysis of CML CP and BC CD34
− progenitors was compared with the genomic coordinates of putative A-to-I editing sites identified in a previously published dataset (35) . In eight CP and eight BC CML primary patient samples, the fraction of sites that contained guanosine bases (representing inosine substitution) compared with adenosine bases was calculated for each patient sample. This comparison revealed a striking enrichment of A-to-G changes in ADAR target sites in BC compared with CP progenitors (Fig. 1D) , demonstrating a shift toward increased RNA editing during CML progression. Furthermore, volcano plot analysis of editing at ADAR target sites revealed ∼16-fold more editing sites with significantly increased editing ratios during BC transformation (Fig. 1E) . A total of 274 sites exhibited significantly different editing rates (Dataset S1), and these sites were located predominantly within Alu repeat sequences (Fig. 1F) . These data suggest that RNA editing activity is not only cell typeand context-specific but also is disease stage-specific and therefore could be a harbinger of disease progression.
By examining the relative levels of ADAR target gene (35) transcripts, we found that 175 of 2,593 putative ADAR target genes were differentially expressed in BC and CP progenitors (Fig. 1G) . Differential expression of a subset of ADAR target genes clearly distinguished BC from CP or cord blood progenitors (Fig. 1G ). In addition, nonnegative matrix factorization, using 200 random start sites, recapitulated these major groupings (Fig. S1H ). Finally, cophenetic correlation coefficients calculated using this human myeloid progenitor dataset, compared with a randomized dataset, also supported three major groupings in the data (Fig. S1I ).
To investigate whether there was evidence of a link between aberrant RNA editing and alternative splice isoform expression in BC versus CP CML, editing ratios at ADAR target sites were calculated for transcripts that were differentially expressed ( Fig. S2 C and D). Editing ratios were found to be increased for significantly differentially expressed transcripts (Fig. S2C) . Moreover, differential isoform expression of ADAR target genes revealed distinct clustering of CML BC versus CP (Fig. S2D) . Thus, the shift in transcriptional patterns associated with increased RNA editing may reflect malignant reprogramming of progenitors in CML.
BCR-ABL Expression Enhances Inflammatory Mediator Gene Expression.
Because qRT-PCR analyses revealed that ADAR1 p150 expression correlated with BCR-ABL levels in BC CML (Fig. 1C) , we sought to investigate the potential mechanisms driving ADAR1 induction in BC CML and the relationship between ADAR1 p150 and BCR-ABL. Both qRT-PCR analyses and RNA-seq studies were performed with CD34
+ cord blood transduced with lentivirus expressing BCR-ABL p210 tagged with GFP or vector control ( Fig 
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A L 0 9 6 7 1 1 .1 L T B P 2 BCR-ABL substrate Crkl by nanoproteomics analysis confirmed functional BCR-ABL activation (Fig. 2B ). These analyses suggested that BCR-ABL may regulate ADAR1 indirectly. In support of this possibility, RNA-seq analyses of lenti-BCR-ABL-transduced cord blood compared with vector-transduced controls identified 45 differentially expressed genes (Fig. 2C ). BCR and ABL1 were up-regulated along with inflammatory mediators such as TNFRSF9 (Fig. 2C) . Other differentially expressed genes included factors involved in ECM function or intercellular junctions (Fig. 2C) . Because TNF pathways, receptors, and other inflammatory mediators also were up-regulated during CML progression ( Fig. 1A and Figs. S1A and S2A), it is conceivable that BCR-ABL regulates ADAR1 p150 through the induction of inflammatory receptor expression.
ADAR1 Promotes Malignant Myeloid Progenitor Expansion and Alter-
native Splicing. Lentiviral ADAR1 overexpression and shRNA knockdown studies were performed to examine the functional consequences of ADAR1 p150 up-regulation. Transduction efficiency of lentiviral vectors driving human ADAR1 (p150) overexpression (lenti-ADAR1) or ADAR1-targeting shRNA (lentishADAR1) was validated in normal cord blood ( Fig. S3 B-E).
Myeloid lineage skewing was observed in colony-forming assays performed with CD34
− cord blood progenitors transduced with lenti-ADAR1 p150, as demonstrated by an increase in the number of macrophage colonies and a corresponding decrease in the number of erythroid burst-forming unit (BFU-E) colonies (Fig. 3A) . This myeloid lineage bias coincided with up-regulation of PU.1-a myeloid transcription factor-and down-regulation of GATA1-an erythroid transcription factor-in colonies from cord blood progenitors transduced with ADAR1 p150 lentivirus ( Fig. 3 B and C) and in CML BC progenitor-derived colonies (Fig. 3 D  and E) . RNA-seq analyses demonstrated an increase in the PU.1/ GATA1 ratio in BC versus CP progenitors (Fig. 3F) . Additionally, network analysis of RNA-seq data revealed down-regulation of genes involved in GATA1-dependent processes (Fig. 3G) .
Short-term culture of normal progenitors transduced with lenti-ADAR1 at increasing multiplicity of infection (MOI) confirmed a positive correlation between PU.1 and ADAR1 expression, whereas the levels of GATA1 expression remained constant (Fig. S3F) . The ADAR1-mediated myeloid lineage skewing recapitulates qRT-PCR data reported with aged human HSC (37) and the expansion of GMP (34) during progression of CML from CP to BC (Fig. S1F ). Because we previously identified production of a misspliced form of GSK3β lacking exons 8 and 9 (7) associated with GMP expansion in CML BC, and because activation of ADAR1 might promote alternative splicing (27) , we performed splice isoform-specific qRT-PCR for GSK3β variants in individual colonies derived from lenti-ADAR1-transduced cord blood or CML CP progenitors. Although GSK3β exon 8-9del was undetectable in cord blood progenitors, in CML CP samples mRNA levels of this variant were increased relative to the exon 9del form, which represents a predominant GSK3β transcript in normal hematopoietic tissues (Fig. S3G) (7) . Together, these results demonstrate that ADAR1 overexpression drives hematopoietic differentiation toward the myeloid lineage, coincident with PU.1 up-regulation and alternative splicing of GSK3β in CML progenitors.
ADAR1 Knockdown Impairs Malignant Myeloid Progenitor Self-
Renewal. Previous reports demonstrate that ADAR1 mediates mouse HSC maintenance (23, 24) ; however the relative effects of down-modulating ADAR1 expression in human LSC versus normal HSC have not been established. In support of a favorable therapeutic index for ADAR1 inhibitory strategies in CML progenitors versus normal cord blood, shRNA knockdown and colony assay experiments showed that lenti-shADAR1 knockdown in normal cord blood progenitors did not affect hematopoietic differentiation (Fig. S3H) , whereas CML CP progenitors transduced with lenti-shADAR1 produced fewer macrophage colonies coupled with increased numbers of BFU-E colonies (Fig. S3I) .
To examine the role of ADAR1 in CML progenitor survival and self-renewal capacity in vivo, CD34
+ human BC CML progenitors were transduced with lenti-shADAR1 or shRNA backbone (lenti-shControl) and transplanted intrahepatically into neonatal RAG2 (Fig. 4A ). In addition, qRT-PCR analysis was performed to confirm ADAR1 p150 knockdown. Similar to experiments in normal cord blood (Fig. S3C) , ADAR1 p150 levels before transplantation were reduced by ∼50% in CML BC progenitors transduced with lenti-shADAR1 as compared with vector controls (Fig. 4A) .
By 10 wk after transplantation, robust leukemic engraftment was detectable in hematopoietic tissues by FACS analysis of human CD45
+ cells (Fig. 4B ). Similar levels of human hematopoietic cell engraftment were detected in bone marrow from mice transplanted with lenti-shADAR1-transduced BC progenitors and lenti-shControl (Fig. 4 C and D) . qRT-PCR analysis confirmed that pooled human progenitors from primary transplantrecipient bone marrow maintained reduced levels of ADAR1 p150, consistent with continued activity of the ADAR1 shRNA after primary engraftment (Fig. 4A) . We transplanted equal 
numbers of human CD34
+ progenitors derived from the bone marrow of primary recipients of lenti-shControl or lenti-shADAR1-transduced cells into secondary recipient mice, and the bone marrow was analyzed for human cell engraftment and CD34
− progenitors by FACS (Fig. 4 E and F) . Notably, serial engraftment potential of shADAR1-transduced CML BC progenitors was reduced considerably (∼20%) compared with shControls (∼50%) (Fig. 4E) . Although leukemic burden was not diminished significantly, the LSC self-renewal capacity was irrevocably reduced by ADAR1 knockdown, suggesting that ADAR1 plays a pivotal role in the propagation of leukemia driven by self-renewing malignant progenitors.
Discussion
Activation of IFN-responsive ADAR1 p150 in primary CML progenitors correlated with increased A-to-I RNA editing following blastic transformation. Full transcriptome RNA-seq analyses suggest that up-regulation of ADAR1 p150 in BC CML may be related to the activation of inflammatory pathways such as cytokines and TNF in advanced disease. Hematopoietic progenitor studies demonstrated that lentivirally enforced ADAR1 p150 expression promotes human myeloid differentiation fate. LentiviralshRNA knockdown of ADAR1 in a xenotransplantation model impaired self-renewal capacity of BC LSC. Together, these data suggest that an inflammatory mediator-driven isoform switch favoring ADAR1 p150 expression drives expansion of malignant progenitors and contributes to CML progression.
ADAR-mediated RNA editing can regulate myriad molecular processes including RNA interference (29) , microRNA function (38) , and RNA stability, localization, nuclear retention, degradation, and alternative splicing (27, (39) (40) (41) . Moreover, high levels of ADAR-mediated RNA editing activity may reflect a reversion to a primitive transcriptional program typical of embryonic stem cells (18) . A previous study demonstrated that ADAR1 was among the top 5% of genes expressed in the mutational evolution of lobular breast cancer (36) , indicating that activation of ADARs may correlate with disease progression in multiple malignant cell types (31) . Although previous studies have shown ADAR1 p110 up-regulation in a murine leukemia model (42) and in pediatric acute leukemias (43) , it should be emphasized that human hematopoietic tissues undergo dramatic changes during aging (44, 45) that are caused in part by increased inflammation and genomic instability (46) .
Our data suggest that inflammatory cues may facilitate selective up-regulation of the IFN-responsive ADAR1 p150 isoform in hematologic malignancies. Using whole-transcriptome sequencing analysis, we found that inflammatory signaling receptors were differentially expressed in BCR-ABL-expressing cord blood. Inflammatory cytokines such as IFN, TNF-α, and other interleukins have been shown to stimulate ADAR1 p150 expression (32, 33) , and IFN regulates HSC quiescence (47) . Together, BCR-ABL-mediated up-regulation of inflammatory pathway receptors could sensitize hematopoietic progenitors to inflammatory stimuli that drive ADAR1 expression and promote CML LSC self-renewal.
Whole transcriptome-based RNA editing analyses revealed that CML progression is accompanied by differential RNA editing. Recent in-depth transcriptomic studies have shown that gene products with predicted A-to-I editing events are significantly enriched in cancer-related pathways (35) . The present study provides further evidence supporting a role for ADARdirected RNA editing in splice isoform diversity in cancer and demonstrates the activation of inflammation-associated RNA editing during the progression of hematologic malignancies. Our results suggest that ADAR1 p150 up-regulation may contribute to blastic transformation of CML driven by the CD34 +
CD38
+ Lin − progenitor and GMP subpopulations. Because ADAR-mediated RNA editing occurs primarily in primatespecific Alu repeat sequences (14, 19, 20) , the activation of RNA editases in human cells may fuel species-specific malignant reprogramming of progenitors to adopt a more primitive stem cell fate under pathological conditions.
Myeloid lineage skewing was observed in response to enforced ADAR1 p150 expression, concomitant with PU.1 activation. Although a previous study in an in vitro model implicated PU.1 in the regulation of murine ADAR1 expression (48), cell typeand niche-specific stimuli may have differential effects on RNA editing, and our studies in human cells, in which 90% of RNA editing occurs in primate-specific Alu sequences, suggest that the converse may occur also. It is conceivable that ADAR1 directly controls PU.1 through RNA editing-dependent effects or via potential transcriptional regulation related to its Z-DNA binding function (41, 49) . In support of the former possibility, DARNED (50), a database compiling RNA editing sites from multiple publications, reports that transcripts of Spi1 (a gene encoding PU.1; chromosome 11, start: 47379732, end: 47400127) showed evidence of A-to-I RNA editing at 28 sites (14) . Future geneexpression analyses and identification of de novo RNA editing sites through analysis of whole-genome and transcriptome DNA-RNA differences (15) in normal HSC harboring enforced ADAR1 p150 expression and LSC will be necessary to dissect further the link between ADAR1 activation PU.1 expression.
In addition to up-regulation of PU.1 in response to ADAR1 p150 overexpression, we also detected production of a misspliced GSK3β variant in colonies derived from CML CP progenitors transduced with lentiviral ADAR1 p150. We have shown previously that this particular form of GSK3β harbors reduced activity and promotes LSC self-renewal via activation of β-catenin (7). In support of a role for ADAR1 in CML LSC self-renewal, we showed in humanized CML xenograft mouse models that ADAR1 knockdown reduced the potential of CML BC LSC for serial transplantation. Given that these CML BC progenitors expressed significantly higher levels of ADAR1 p150 than did normal cord blood progenitors, we expect that LSC are relatively more dependent on IFN-responsive ADAR1 activity (24) . Together these data suggest that inflammation-dependent activation of the ADAR1 p150 editase promotes CML progression. Aberrant ADAR1 activation in CML endows myeloid progenitors with self-renewal capacity leading to LSC generation. Thus, inhibition of ADAR1 activity could represent an effective strategy to prevent LSC-driven relapse in CML while sparing normal HSC populations. Furthermore, ADAR1-mediated RNA editing activation could prove to be a diagnostic and prognostic indicator of disease progression with important implications for other cancer stem cell-driven malignancies.
CML BC Progenitors

RAG2 -/-c -/-
Materials and Methods
Primary samples from CML patients were obtained from consenting patients at the University of California San Diego, Stanford University, and the University of Toronto Health Network. FACS-purified progenitor cells from primary samples or normal cord blood were processed for RNA-Seq, qRT-PCR, and for in vitro and xenotransplantation studies. + cells then were purified by magnetic bead separation (MACS; Miltenyi). Hematopoietic progenitors or GMP were purified by FACS using human-specific CD34 and CD38 antibodies and a lineage mixture as previously described (1, 2). For RNA-seq and qRT-PCR analyses, FACS-purified progenitor cells from normal cord blood, CML chronic phase (CP), or CML blast crisis (BC) samples were sorted directly into RLT buffer (Qiagen) as described previously (3). Lysates were processed for RNA extraction using RNeasy Micro kits (Qiagen).
Transcriptome Profiling and Analysis by RNA-Seq. RNA extracted from 50,000 normal cord blood, CML CP, or CML BC progenitor cells (20 ng) was analyzed for purity, and samples with RNA integrity numbers ≥7 were prepared for RNA-seq analysis. RNA was processed using SMART cDNA synthesis (Clontech) and NEBNext paired-end DNA Sample Prep Kit (New England BioLabs) to prepare libraries. Samples were sequenced on Illumina HiSeq2000 instruments with an average of ∼161 million Chastity-passed paired reads, 50 bp in length, per sample.
RNA-Seq Whole-Gene Analysis. As described previously (4), the paired-end Chastity-passed reads were aligned to the human reference genome (version hg19/GRch37) plus exon junction sequences constructed from all known transcript models in Refseq, EnsEMBL and known genes from the University of California, Santa Cruz (UCSC) database using Burrows-Wheeler Aligner software (version 0.5.7) (5) with default parameters except that the Smith-Waterman alignment was disabled. After the alignment, the reads that spanned exon-exon junctions and did not map to the human reference genome were repositioned as large-gapped alignments in the genome based on the coordinates of the exons used to construct exon junction sequences. For gene-expression quantification, we developed gene-coverage analysis software algorithms to calculate the per-base coverage across all exons annotated by EnsEMBL (version 59) and to sum up the coverage across all nonredundant exonic bases. From the coverage, we computed read counts and normalized the read counts by gene lengths and library depths, i.e., RPKM (6) . Fold changes in gene-expression levels were calculated by transforming all RPKM values using the equation 1 + X.
RNA-Seq Isoform Analysis. For isoform analysis, paired reads were aligned to the hg19 reference genome with Alexa-seq (7), and isoform expression levels were computed with the Cufflinks software packages (v.1.1.0) (8) using default parameters plus upper-quartile normalization. A filtered version of the UCSC KnownGenes (9) was used as the input reference genome annotation; isoforms for which RNA-seq reads did not support (i.e., align to) every exon and splice junction were filtered out of the KnownGenes collection before input into Cufflinks.
Differential Gene Expression, Network, and Pathway Analyses. Unsupervised hierarchical clustering was performed using log2-transformed RPKM values that were subtracted by the median across each row (genes) for centering. The 2,228 genes expressed differentially in BC and CP CML were used to identify significantly enriched pathways and networks of differentially expressed genes using Ingenuity Pathway Analysis (IPA) (Ingenuity Systems, www.ingenuity.com), and the Reactome Functional Interaction (FI) plugin (10) on Cytoscape (version 2.8.1) essentially as previously described (11) . The significantly enriched pathways from the Reactome FI plugin were filtered at false-discovery rate (FDR) <0.01, and the overlapping relationship between the significant pathways was visualized using EnrichmentMap (version 1.2) (12) with the Reactome FI plugin. The genes were ranked by the significance of differential expression represented in FDR.
Adenosine-to-Inosine RNA Editing Analysis of RNA-Seq Data. The number of RNA-seq reads specifying an A(T) or G(C) was determined at each of the putative RNA editing sites identified in previous work performed by others (13) for each CP (n = 8) and BC (n = 8) sample. To be considered as a site, that site must have at least five overlapping RNA-Seq reads in each of the eight CP samples and in each of eight BC samples. Then, for each site, the percentage of reads that contained a G was calculated for each sample. The percentages were averaged in eight CP and eight BC samples, and then the differences between these two percentages were computed (BC − CP). A two-sided t test was performed using the BC percentages and the CP percentages for each site. For sites with associated P values < 0.05, we computed the difference in average editing percentages (Fig. 1D) . RNA editing fold changes were calculated by transforming all editing percentages using the equation 1 + X.
qRT-PCR. Five thousand to fifty thousand progenitor cells were CD34-selected or FACS-purified into RLT buffer, total RNA was isolated, and cDNA was synthesized as described previously (2) . Primers were designed to detect human ADAR1 (total and isoform-specific), PU.1, GATA1, BCR-ABL, GSK3β, and HPRT (Table S2) . qRT-PCR was performed in duplicate on an iCycler using SYBR GreenER Super Mix (Invitrogen), 5 ng of template mRNA, and 0.4 mM of each forward and reverse primer. HPRT mRNA transcript levels were used to normalize each gene.
Cell Treatments, Lentivirus Preparation, and Transduction of Hematopoietic Progenitors. We have developed a lentiviral human BCR-ABL1 vector in the pCDH-EF1-T2A (skip)-GFP lentiviral vector (System Biosciences) (Fig. S3A) . Vector control consists of the pCDH-GFP backbone. Lentiviral vector plasmids expressing ADAR1 p150 (no. OHS5898-101190065), or GFP-expressing backbone vector or shRNA specific to human ADAR1 (no. RHS4531), or backbone vector containing a nontargeting control shRNA (shControl), were purchased from Open Biosystems (Thermo Fisher Scientific).
For in vitro treatment of normal cord blood progenitors with inflammatory molecules, CD34
+ cord blood cells were incubated in microwell plates containing StemPro (Invitrogen) medium supplemented with human IL-3, GM-CSF, and stem cell factor (SCF) in the presence of IFN-γ, TNF-α (both from Cell Signaling Technology), or vehicle control for 48 h at 10-fold increasing concentrations. The concentrations used for TNF-α were 5 ng/mL, 50 ng/mL, 500 ng/mL, and 5 μg/mL, and for IFN-γ concentrations were 50 ng/mL, 500 ng/mL, 5 μg/mL, and 50 μg/ mL. RNA was extracted, qRT-PCR analysis was performed for ADAR1 isoforms as described above, and data were normalized to HPRT expression levels.
For lentivirus production, all lentiviruses were generated as described previously (2), and transduction efficiencies were validated by transduction of 293T cells and normal cord blood. Transductions of human hematopoietic stem cell and CML progenitors or GMP were performed at a multiplicity of infection (MOI) of 50-200. For transduction of human cord blood with lenti-BCR-ABL or vector control for RNA-seq, qRT-PCR, and nanoproteomics analyses, CD34
+ cells were selected using magnetic beads (MACS; Miltenyi Biotec), and cells were transduced and cultured for 2-5 d in microwell plates containing StemPro (Invitrogen) medium supplemented with human IL-3, GM-CSF, and SCF. RNA was harvested in RLT buffer as described above for qRT-PCR and RNA-seq analyses, and a subset of wells was harvested in lysis buffer for nanoproteomics analyses.
For transduction of leukemia stem cells (LSC) or human cord blood for in vitro colony assays, cells were stained and sorted by FACSAria (Becton Dickinson) for the CD34 + CD38 + Lin − PI − cells, which then were transduced with lentiviruses in 96-well plate (10,000-20,000 cells per well) for 48-72 h and then transferred to methylcellulose for colony assays as described previously (2, 3). Transduction of normal cord blood progenitors with lentiviral vectors driving human ADAR1 (p150) overexpression (lenti-ADAR1) or ADAR1-targeting shRNA (lentishADAR1) compared with control backbone lentiviral vectors showed that lenti-ADAR1 conferred approximately two-to threefold higher expression than endogenous human ADAR1 p150 levels (Fig. S3B) , whereas lenti-shADAR1 transduction resulted in ∼50% knockdown of endogenous human ADAR1 as confirmed by qRT-PCR (Fig. S3C) . For in vivo experiments using lenti-shADAR1 knockdown, qRT-PCR analysis of lentishADAR1-transduced CML BC progenitors before primary transplant showed a 50% reduction in ADAR1 p150 mRNA levels compared with control vector (shControl) (Fig. 4A) . Similarly, qRT-PCR analysis of pooled human progenitor cells harvested from the bone marrow of primary transplant recipients of CML BC progenitors transduced with lenti-shADAR1 maintained a 50% reduction in ADAR1 p150 mRNA levels compared with control vector (shControl) (Fig. 4A) . For lenti-ADAR1 transduction and qRT-PCR in individual colonies (Fig. S3G) , cord blood (n = 3) and CML CP (n = 3) progenitors were transduced with lenti-ADAR1 p150 or vector (ORF) control (48 h), followed by coculture (48 h) with mouse bone marrow stromal cells as previously described (14) and then were transferred to methylcellulose (2 wk). Individual ADAR1 p150 + colonies were collected and processed for qRT-PCR with splice isoform-specific primers for lentivirus-driven ADAR1 p150, misspliced GSK3β (exons 8 and 9 deleted), and GSK3β (exon 9 deleted) and were normalized to HPRT.
Hematopoietic Progenitor Colony Assays. Following lentivirus transduction of FACSAria-sorted cord blood or CML patient progenitors, GFP + cells were sorted into MethoCult medium (50-100 cells per well of a 12-well plate). After 2 wk, total colonies were counted, and individual colonies for each condition were picked and replated in fresh MethoCult medium as previously described (3). Secondary colonies were counted after an additional 2 wk of culture. Nanofluidic Phospho-Proteomic Immunoassay. Nanofluidic phosphoproteomic immunoassay experiments were performed with the Nanopro 1000 instrument (Cell Biosciences), and samples were analyzed in triplicate. Samples were prepared using 4 nL of 10 mg/mL lysate diluted to 0.2 mg/mL in 200 nL HNG [20 mM Hepes (pH 7.5), 25 μM NaCl, 100 μL/mL glycerol, Sigma Phosphatase Inhibitor Mixture 1 diluted 1:100, and Calbiochem Protease Inhibitor diluted 1:100]. Two hundred nanoliters of sample mix containing internal pI standards was added. The Firefly system first performed a charge-based separation (isoelectric focusing) in a 5-cm-long, 100-μm i.d. capillary. Predicted pI values were calculated with Scansite. Each sample was run on a panel of different pH gradients (pH 3-10 and pH 2-11) to optimize the resolution of different peak patterns. After separation and photoactivated in-capillary immobilization, CRKL was detected using CRKL-specific antibody (Cell Signaling Technology). B2-microglobulin (B2M) (Upstate) antibody was used to normalize the amount of loaded protein. The peaks were quantified by manually selecting the start and end of each peak and a flat baseline and calculating the area under the curve. The nanoproteomics data were normalized to B2M by dividing the measured peak area for the protein of interest by the measured peak area for B2M.
Statistical Analysis. qRT-PCR. ADAR1 isoforms, BCR-ABL, PU.1, GATA1, and GSK3β expression data were assessed for normal distribution. The Student t test or one-way ANOVA was used to calculate changes in ADAR1 expression levels based on whether two or more groups were compared. Results were expressed as means ± SEM. Correlation analysis of HPRT-adjusted expression levels between groups (ADAR1, BCR-ABL, PU.1, GATA1, and GSK3β) was performed by Pearson correlation and calculation of r 2 values. RNA-seq. For differential gene-expression analysis, we used DESeq 36 (version 1.6.1) in R (version 2.14.1) and identified differentially expressed genes at an FDR of 10%. For hierarchical clustering of RNA-Seq-based gene-expression analyses, we used the complete linkage and Spearman's rank correlation coefficient as distance metrics for both sample and gene clusterings. The clustering results were visualized using Treeview (Java Cluster software, available at http://bonsai.ims.u-tokyo.ac. jp/~mdehoon/software/cluster/software.htm). For the presentation in Fig. 1 , we rotated the subtree of BC-01, CB-02, CB-03, and BC-25 to align BC-25 with other BC samples for comparison. Volcano plots of comparisons of RNA editing and isoform expression were performed by plotting the absolute value of the base 10 logarithm of the t test P values and the base 2 logarithm of the fold change in expression, and reference lines were plotted where P < 0.05 and at fold changes of ±2.5 fold. Hematopoietic progenitor assays. The Student t test was used to compare colony counts in CML BC versus CML CP and normal human progenitors. Statistical analyses were performed with the aid of FlowJo, GraphPad Prism, Microsoft Excel, R, and SAS software. Results were expressed as means ± SEM. analyzed by qRT-PCR with isoform-specific primers detecting human ADAR1 p150 (C) and p110 (D), and cycle threshold (Ct) values were normalized to HPRT. P < 0.05 compared with normal cord blood by Student t test. (E) RNA from granulocyte-macrophage progenitors (GMP) that were FACS-sorted from normal cord blood (n = 3), CML CP (n = 5), and CML accelerated phase (AP, n = 1)/BC (n = 2) samples was analyzed by qRT-PCR with isoform-specific primers detecting
Legend continued on following page human ADAR1 p150, and Ct values were normalized to HPRT. P < 0.05 compared with normal cord blood by Student t test. (F) Representative FACS plots of normal, CML CP, and CML BC peripheral blood samples. CMP, common myeloid progenitors; GMP, granulocyte-macrophage progenitors; MEP, megakaryocyteerythroid progenitors. (G) Relative ADAR1 p150 expression levels were measured by qRT-PCR in normal cord blood (n = 1) incubated with IFN-γ or TNF-α for 48 h, and linear regression analysis was performed comparing p150 mRNA expression with IFN-γ (r 2 = 0.8098) and TNF-α (r 2 = 0.8349) relative concentration. (H) Consensus matrix from 200 random starts, using nonnegative matrix factorization clustering of the differentially expressed genes in BC versus CP CML, computed at k = 3 for the above samples. Dark blue indicates that samples were never clustered in the same cluster, and red indicates that samples always were in the same cluster; the major clusters found previously are recapitulated. Patients treated with imatinib are denoted in blue. (I) Cophenetic correlation coefficients corresponding to consensus matrices computed at factorization ranks between 2 and 15. The blue plot indicates the cophenetic correlation coefficients calculated using our dataset, and the red plot indicates the cophenetic correlation coefficients calculated using a randomized dataset, supporting three major groupings in the data. IL2RG  IL3RA  IL23A  IL3RA   IL1B  TNFSF4 IL12RB1   IL2RA  IRF1  IL15RA  IL12RB1  IL13RA1  IL2RA  STAT1   IFNAR2  TNFRSF1A  TNFRSF14   IL1B   L12RB1  I   IL2RA   )  e  u  l  a  V  P  (  0  1  g , and ADAR3 (ADARB2) over individual CP (n = 7) and BC (n = 5) CML samples. (C) Editing percentages in differentially edited ADAR target sites located in transcripts that were differentially expressed in BC (n = 5) and CP (n = 7) CML. All sites shown were differentially edited at a significance of P < 0.05 by Student t test. (D) The top 65 isoforms of ADAR targets differentially expressed in BC CML progenitors and CP samples were identified and presented as a heatmap for each transcript in each sample (n = 7 CP, n = 5 BC). The clustergram was generated using (average) standardized Euclidean distance between (clusters of) expression vectors. Dataset S1
